BIOGARAN in the news

Biogaran, a generic drug manufacturer, has hired Paul Simon as Director of Transformation following its acquisition by BC Partners and a new strategic development phase.

French Prime Minister Gabriel Attal pledges "exceptional vigilance" over the sale of generic drug manufacturer Biogaran to any non-European buyer.

Biogaran's employee count grew by 12.9% from 1,019 in 2023 to 1,151 in 2026.

The ANSM suspended marketing authorizations for several generic drugs, including Biogaran's EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL, due to unproven bioequivalence studies and initiated product recalls.

The ANSM has suspended the marketing authorizations and recalled lots for several generic drugs, including those from Biogaran, due to unproven bioequivalence from studies conducted by Synapse Labs.

Biogaran, a generic drug manufacturer, is undergoing a major digital transformation, migrating its systems to SAP S/4HANA on Google Cloud to improve supply chain management, prevent drug shortages, and automate operations.

Erick Roche returns to Biogaran as Chairman and CEO to lead the company's growth in the generic and biosimilar drug markets.

A French generic drug manufacturer with 1,108 employees specializing in high-quality prescription and over-the-counter medications.

Lundbeck and Biogaran are engaged in cross-border patent litigation over nalmefene, a drug used to treat alcohol dependence.

Biogaran launched an ad campaign with TBWAParis for its OTC Biogaran Conseil range, emphasizing the effectiveness of molecules through humorous films and a distinctive visual style.

Biogaran launched a new marketing campaign for its Biogaran Conseil over-the-counter medicine line, emphasizing active ingredients and using humor to boost visibility.

Biogaran launched an advertising campaign for its over-the-counter medication range, Biogaran Conseil, featuring humorous spots about specific active ingredients.

Servier's sale of major generic manufacturer Biogaran to a British fund threatens French health sovereignty and the supply of essential medicines.

Biogaran, France's leading generic drug supplier, is being sold by Servier to a British investment fund, raising concerns about national health sovereignty and essential medication supply.

Servier's sale of Biogaran to a British investment fund sparked controversy over France's health sovereignty and industrial impact.

Bpifrance and BC Partners have completed the acquisition of generic drug manufacturer Biogaran to secure its domestic operations and strategic role in France.

French MP Aurélie Trouvé is scrutinizing the acquisition of generic drug leader Biogaran by a British fund to ensure production remains in France.

British fund BC Partners and Bpifrance have acquired French generic drug leader Biogaran, sparking a parliamentary investigation into production and employment guarantees.

British private equity firm BC Partners acquires a majority stake in French generic drug leader Biogaran following government approval.

BC Partners and Bpifrance completed the acquisition of Biogaran, a French generic drug leader, from Servier, with Erick Roche returning as CEO to lead its next growth phase.